Synonyms: Aklief® | CD5789 | compound 15b [PMID: 29706423]
trifarotene is an approved drug (FDA (2019))
Compound class:
Synthetic organic
Comment: Trifarotene (CD5789) is a RARγ-selective agonist that was developed as a topical anti-acne therapeutic [1-2,4].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Trifarotene (CD5789) has completed Phase 3 clinical trial in patients with acne vulgaris, including the long term safety study NCT02189629 [3]. FDA approval for clinical use in patients with acne was granted in October 2019 (for Aklief®, a 0.005% topically applied cream). |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02189629 | CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris | Phase 3 Interventional | Galderma R&D |